Observational Study of Safety and Effectiveness of Treatments for Adults with Alopecia Areata

What this Trial Is About

Researchers are conducting a prospective observational study to follow adults diagnosed with alopecia areata AA who are under the care of dermatology providers. The study aims to gather long-term information on the safety and effectiveness of AA treatments in real-world patients. Since knowledge about long-term treatment effects remains limited even after drug approval, enrolling a large and diverse group of patients will help better understand the disease and treatment outcomes. Participants will be enrolled from multiple clinical sites across North America, with no upper age limit and a target of about 5,000 subjects. The registry collects data on medications prescribed or started at enrollment, patient-reported outcomes, clinician-reported outcomes, and information on comorbidities and adverse events. Personal information is also gathered to link with other databases for further research on clinical and economic aspects of AA treatment. During the study, participants will have evaluations every six months for up to 10 years, including assessments like the Severity of Alopecia Tool SALT, Dermatology Life Quality Index DLQI, and work productivity measures. Researchers will monitor epidemiology, disease progression, management, and outcomes over at least 10 years from the last patients enrollment. The study focuses on collecting detailed real-world data to inform future clinical decisions and regulatory evaluations.

CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry